.jpg){kind=logo}
Cardiac Amyloidosis: On the Road
Join us for a Cardiac Amyloidosis symposium in your region.
Cardiac Amyloidosis: Tips and Tricks for Diagnosis and Management
Tuesday, July 27th, 2021
6:00 pm to 8:00 pm (EDT)
Fee: Free for members, $75 for non-members. Join ASNC and Save
Credits: Earn 2* AMA PRA Category 1 Credits™
*Credits subject to change
Program Director:
Prem Soman, MD, PhD, MASNC
Associate Chief of Cardiology
Director, Cardiac Amyloidosis Center
University of Pittsburgh Medical Center
Pittsburgh, PA
Credits: Earn 2* AMA PRA Category 1 Credits™
*Credits subject to change
Program Director:
Prem Soman, MD, PhD, MASNC
Associate Chief of Cardiology
Director, Cardiac Amyloidosis Center
University of Pittsburgh Medical Center
Pittsburgh, PA
Moderator: Prem Soman, MD, PhD, MASNC
| July 27, 2021 | Agenda | ||
| Eastern Daylight Time | Title | Speaker | |
| 6:00 PM | Welcome and Introduction | Prem Soman, MD, PhD | |
| 6:05 PM | What is cardiac amyloidosis? When should you suspect it? |
Brent Medoff, MD | |
| 6:15 PM | Diagnosis of cardiac amyloidosis | Joshua Levenson, MD | |
| 6:25 PM | The V142I mutation | Saurabh Malhotra, MD, MPH | |
| 6:35 PM | Polyneuropathy in amyloidosis | Sasa Zivkovic, MD, PhD | |
| 6:45 PM | Serum studies in cardiac amyloidosis: When to call a hematologist? |
Alison Sehgal, MD | |
| 6:55 PM | Treatment of heart failure in cardiac amyloidosis | Mary Keebler, MD | |
| 7:05 PM | Specific therapies for cardiac amyloidosis | Prem Soman, MD, PhD | |
| 7:15 PM | Common considerations in cardiac amyloidosis - Questions from clinical practice |
Drs. Malhotra and Soman | |
| 8:00 PM | Adjourn | ||
Boston Transthyretin Cardiac Amyloid Virtual Symposium
July 14th & 15th, 2021
6:00 pm to 7:30 pm (EDT)
Fee: Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.0* AMA PRA Category 1 Credits™
*Credits subject to change
Program Director: Sharmila Dorbala, MD, MPH, MASNC
Moderator: Sarah Cuddy, MD, BCh
| July 14, 2021 | Agenda | |
| Eastern Daylight Time | Title | Speaker |
| 6:00 pm - 6:05 pm | Welcome, introduction and knowledge questions |
Sarah Cuddy, MD, BCh |
| 6:05pm - 6:25 pm | Pathogenesis, clinical features and laboratory evaluation of ATTR cardiac amyloidosis |
Frederick Ruberg, MD |
| 6:25 pm - 6:45 pm | Advanced imaging for the noninvasive diagnosis of ATTR cardiac amyloidosis |
Sharmila Dorbala, MD, MPH |
| 6:45 pm - 7:15 pm | Challenging cases from an established amyloidosis program |
Sarah Cuddy, MB, BCh |
| 7:15 pm - 7:30 pm | Discussion: Stump the Stars: Cases from New England Sites |
Discussion |
Moderator: Nishant Shah, MD
| July 15, 2021 | Agenda | ||
| Eastern Daylight Time | Title | Speaker | |
| 6:00 pm - 6:05 pm | Welcome | Nishant Shah, MD | |
| 6:05 pm - 6:25 pm | When do I consider evaluation for ATTR cardiac amyloidosis? Perspective of a heart failure physician |
James Udelson, MD | |
| 6:25 pm - 6:45 pm | How do I treat ATTR cardiac amyloidosis? | Rodney Falk, MD | |
| 6:45 pm - 7:15 pm | Challenging cases from an emerging cardiac amyloidosis program |
Nishant Shah, MD | |
| 7:15 pm - 7:30 pm | Discussion: Stump the Stars: Cases from New England Sites |
Discussion | |
| 7:30 pm | Adjourn | ||
The Cardiac Amyloidosis: On the Road programs will:
- Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM.
- Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM.
- Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.
- Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings.
- Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.
- Describe amyloidosis, including specific types, cardiac features and disease burden.
- Identify barriers to identification and diagnosis of patients suspected of ATTR.
- Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
- Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis.
- Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report.
- Demonstrate understanding of current treatments for patients with ATTR-CM.
If you have any questions about registration, please contact info@asnc.org
These programs are supported by educational grants from Pfizer.
Cancellation Policy
Notification of cancellation must be received in writing to: info@asnc.org. The Course registration fee is partially refundable (50%) if you cancel 15 days in advance of the meeting. You must cancel your registration in writing 15 days in advance to receive any refund. Any cancellation after this deadline will not result in a refund. Please allow three weeks for processing. Telephone cancellations are not eligible for a refund.